Spots Global Cancer Trial Database for NGS Combined With RNAseq on Tumor Immune Escape in NSCLC
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: NGS Combined With RNAseq on Tumor Immune Escape in NSCLC
Official Title: Study on the Effect of NGS Combined With RNAseq on Tumor Immune Escape in Advanced Non-small Cell Lung Cancer EGFR and ALK Mutant Negative Patients
Study ID: NCT03764917
Conditions
Interventions
Study Description
Brief Summary: Study on the tumor immune escape in advanced non-small cell lung cancer patients with EGFR and ALK mutant negative by NGS combined with RNAseq
Detailed Description: Study on the tumor immune escape in advanced non-small cell lung cancer patients with EGFR and ALK mutant negative by NGS combined with RNAseq. Detecting non-small cell lung cancer patient NGS and RNAseq data before first-line chemotherapy, after two cycles chemotherapy and after disease progression.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Shanghai Pulmonary Hospital, Shanghai, Shanghai, China
Contact Details
Name: Yayi He, MD, PHD
Affiliation: Shanghai Pulmonary Hospital, Tongji University
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
